Literature DB >> 6088074

Excision of an intact intron as a novel lariat structure during pre-mRNA splicing in vitro.

B Ruskin, A R Krainer, T Maniatis, M R Green.   

Abstract

To study the mechanisms of RNA splicing we have analyzed the products generated by in vitro processing of a truncated 32P-labeled human beta-globin RNA precursor that contains the first two exons and the first intervening sequence (IVS1). Six major RNA products were detected and characterized. The first detectable RNA processing event is cleavage at the 5' GT of IVS1. Subsequently, accurately spliced RNA and the excised, intact IVS1 are simultaneously observed. The IVS1-containing RNA processing products have several unusual properties, which include: anomalous electrophoretic mobilities on polyacrylamide gels; a block to reverse transcription near the 3' end of IVS1; the presence of a nuclease-resistant component within IVS1. The block to reverse transcription and the nuclease-resistant component map to the same site near the 3' end of IVS1. The nuclease-resistant component appears to be a modified adenosine residue that contains an RNA branch. Based upon these and other structural studies we propose that the 5' end of IVS1 is joined by a 2'-5' phosphodiester linkage to the A residue in the RNAase T1 oligonucleotide ACTCTCTCTG located 28-37 nucleotides upstream from the IVS1 3' end. The IVS1 is therefore in the form of a lariat. These results imply that sequences within IVS1 actively participate in splicing.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088074     DOI: 10.1016/0092-8674(84)90553-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  271 in total

1.  Sequences upstream of the branch site are required to form helix II between U2 and U6 snRNA in a trans-splicing reaction.

Authors:  G Ast; T Pavelitz; A M Weiner
Journal:  Nucleic Acids Res       Date:  2001-04-15       Impact factor: 16.971

2.  cis-acting sequences involved in exon selection in the chicken beta-tropomyosin gene.

Authors:  M E Gallego; L Balvay; E Brody
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

3.  Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2 beta.

Authors:  Zhihong Jiang; Hao Tang; Necat Havlioglu; Xiaochun Zhang; Stefan Stamm; Riqiang Yan; Jane Y Wu
Journal:  J Biol Chem       Date:  2003-03-20       Impact factor: 5.157

4.  Expression in transgenic tobacco of the bacterial neomycin phosphotransferase gene modified by intron insertions of various sizes.

Authors:  J Paszkowski; A Peterhans; R Bilang; W Filipowicz
Journal:  Plant Mol Biol       Date:  1992-08       Impact factor: 4.076

5.  Ser/Thr-specific protein phosphatases are required for both catalytic steps of pre-mRNA splicing.

Authors:  J E Mermoud; P Cohen; A I Lamond
Journal:  Nucleic Acids Res       Date:  1992-10-25       Impact factor: 16.971

6.  Detection and characterization of a factor which rescues spliceosome assembly from a heat-inactivated HeLa cell nuclear extract.

Authors:  P Delannoy; M H Caruthers
Journal:  Mol Cell Biol       Date:  1991-07       Impact factor: 4.272

7.  Model for tissue specific Calcitonin/CGRP-I RNA processing from in vitro experiments.

Authors:  R A Bovenberg; G J Adema; H S Jansz; P D Baas
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

8.  Unusual branch point selection involved in splicing of the alternatively processed Calcitonin/CGRP-I pre-mRNA.

Authors:  G J Adema; R A Bovenberg; H S Jansz; P D Baas
Journal:  Nucleic Acids Res       Date:  1988-10-25       Impact factor: 16.971

9.  Size and position of intervening sequences are critical for the splicing efficiency of pre-mRNA in the yeast Saccharomyces cerevisiae.

Authors:  F J Klinz; D Gallwitz
Journal:  Nucleic Acids Res       Date:  1985-06-11       Impact factor: 16.971

10.  In vitro splicing of pre-messenger RNA with extracts from 5-fluorouridine-treated cells.

Authors:  J R Patton
Journal:  Biochem J       Date:  1994-01-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.